VIGL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	66 652.00
Average Volume	88 767.00
Market Cap	96.97M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.210
ATR14	$0.0150 (0.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Kaufmann Petra	Buy	330 000	Stock Option Grant (Right to Buy)
2024-03-18	Kaufmann Petra	Buy	0
2024-03-01	Booth Bruce	Buy	34 612	Stock Option Grant (Right to Buy)
2024-03-01	Bruhn Suzanne Louise	Buy	24 073	Stock Option Grant (Right to Buy)
2024-03-01	Blanchard Cheryl R	Buy	24 761	Stock Option Grant (Right to Buy)

INSIDER POWER
99.98
Last 93 transactions
Buy: 32 103 135 \| Sell: 31 582 660

Volume Correlation

Long: 0.03 (neutral)

Short: -0.20 (neutral)

Signal:(48.769) Neutral

Vigil Neuroscience, Inc. Correlation

10 Most Positive Correlations
RMRM	0.816

10 Most Negative Correlations
NETE	-0.824
SHSP	-0.81
BOCH	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vigil Neuroscience, Inc. Correlation - Currency/Commodity

0.25
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.50
( neutral )

-0.25
( neutral )

-0.05
( neutral )

Vigil Neuroscience, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2023
Revenue:	$0
Gross Profit:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2022
Revenue:	$0
Gross Profit:	$-1.01M (0.00 %)
EPS:	$-2.14

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.531

Financial Reports:

No articles found.

Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.